SECOVIT - Sequence-based analysis of interactions of SARS-CoV-2, respiratory viral co-infections, and T-cell immunity: clinical implications

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 01KI20185A

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

  • Research Location

    Germany, Europe
  • Lead Research Institution

    Universität zu Köln Universität Duisburg-Essen
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



discovery - The outbreak of the new virus SARS-CoV-2 is a major problem at a global scale. Viral evolution is a major characteristic of all RNA viruses leading to accelerated evolution and adaptability to new environments. Our working hypothesis is that specific SARS-CoV-2 variants will be selected, as the virus is passing through a vast set of individuals with diverse HLA alleles and co-infections. The mutations fixed in this process can affect viral properties such as transmission or replication rates, that finally may modulate coronavirus disease (COVID-19) progression. The overall goal of this interdisciplinary consortium is to elucidate whether the HLA background and respiratory viral co-infections play a role in SARS-CoV-2 evolution and adaptation to different Human populations as well as in the severity of COVID-19. The specific scientific questions of the consortium are: 1) to characterise the genetic variability of SARS-CoV-2 in NRW over time of the current outbreak and from possible future infections, and in comparison to other geographic regions; 2) to define the role of HLA as driving force for SARS-CoV-2 evolution and as a determinant for disease severity, using data from our patients as well as prevalence data from other countries; and 3) to define the role of respiratory viral co-infections and their implications for the severity of COVID-19 outcome and SARS-CoV-2 evolution. This will enable to optimise medical and quarantine measures. HLA associations with SARS-CoV-2 genomes can be exploited for the design of T-cell based vaccines